quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:14:54·1120d
NEWSRelease
Maxpro Capital Acquisition Corp. logo

Apollomics, A Company Developing Novel Oncology Therapies To Address Difficult-To-Treat Cancers, Announces Closing Of Business Combination And Listing On Nasdaq

JMAC· Maxpro Capital Acquisition Corp.
Industrials
Original source

Companies

  • JMAC
    Maxpro Capital Acquisition Corp.
    Industrials

Related

  • 13D/G1108d
    SEC Form SC 13G/A filed by Maxpro Capital Acquisition Corp. (Amendment)
  • SEC1109d
    SEC Form 15-12G filed by Maxpro Capital Acquisition Corp.
  • SEC1119d
    SEC Form 10-K filed by Maxpro Capital Acquisition Corp.
  • SEC1120d
    Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits
  • PR1120d
    Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
  • NEWS1121d
    Reported Late Wednesday March 29, Apollomics Announces Completion Of Business Combination With Maxpro Capital Acquisition Corp. And Listing On Nasdaq; Expected To Commence Trading On March 30, 2023, On The Nasdaq Capital Market Under The Symbols "APLM"
  • INSIDER1121d
    SEC Form 4 filed by Chen Yi-Kuei (Alex)
  • INSIDER1121d
    SEC Form 4 filed by Wu Soushan
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022